Pharmaceuticals - Community Register


Community register of medicinal products for human use


Product information

Invented name: Olazax   
Auth. number : EU/1/09/597
Active substance : Olanzapine
ATC: Anatomical main group: N - Nervous system
Therapeutic subgroup: N05 - Psycholeptics
Pharmacological subgroup: N05A - Antipsychotics
Chemical subgroup: N05AH - Diazepines, oxazepines, thiazepines and oxepines
Chemical substance: N05AH03 - olanzapine
(See WHO ATC Index)
Indication: Adults
Olanzapine is indicated for the treatment of schizophrenia.
Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.
Olanzapine is indicated for the treatment of moderate to severe manic episode. In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.
Marketing Authorisation Holder: Glenmark Pharmaceuticals s.r.o.
Hvězdova 1716/2b, 140 78 Praha 4, Česká republika.
EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
15/12/2009 Centralised - Authorisation EMEA/H/C/1087 (2009)10333 of 11/12/2009
18/05/2010 Centralised - Variation EMEA/H/C/1087/WS/2 (2010)3234 of 12/05/2010
11/02/2011 Centralised - Variation EMEA/H/C/1087/WS/68 (2011)922 of 9/02/2011
12/01/2012 Centralised - Variation EMEA/H/C/1087/IG/132/G
Updated with Decision(2012)1183 of 17/02/2012
21/02/2012 Centralised - Variation EMEA/H/C/1087/WS/202 (2012)1183 of 17/02/2012
10/07/2012 Centralised - Variation EMEA/H/C/1087/WS/262 (2012)4848 of 6/07/2012
16/10/2012 Centralised - Variation EMEA/H/C/1087/WS/285 (2012)7397 of 15/10/2012
4/12/2012 Centralised - Variation EMEA/H/C/1087/WS/319 (2012)9096 of 30/11/2012
23/01/2014 Centralised - Variation EMEA/H/C/1087/WS/424
Updated with Decision(2014)6089 of 22/08/2014
26/08/2014 Centralised - Renewal EMEA/H/C/1087/R/14 (2014)6089 of 22/08/2014
7/10/2016 Centralised - Variation EMEA/H/C/1087/IG/698
Updated with Decision(2017)6110 of 05/09/2017
9/02/2017 Centralised - Variation EMEA/H/C/1087/IB/WS/1098/G
Updated with Decision(2017)6110 of 05/09/2017
23/02/2017 Centralised - Variation EMEA/H/C/1087/IG/770/G
Updated with Decision(2017)6110 of 05/09/2017
7/09/2017 Centralised - Yearly update (2017)6110 of 5/09/2017